J B Chemicals and Pharmaceuticals Ltd
Jason D'Souza has a vast amount of experience in Investor Relations, Corporate Communications, and ESG functions. Jason has held various leadership roles in well-known pharmaceutical companies such as JB Pharma, JB Chemicals & Pharmaceuticals Limited, and Glenmark Pharmaceuticals. Throughout their career, Jason has been a key member of the Executive Leadership team, overseeing strategic projects, M&A, Corporate Branding, and CSR functions. Jason has a strong educational background with a Masters in Management and a PGD in Communications.
This person is not in any offices
J B Chemicals and Pharmaceuticals Ltd
J. B. Chemicals & Pharmaceuticals Limited is a pharmaceutical company. The Company manufactures and markets a range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs). The Company's business segments include domestic formulation business, exports and API business. The Company markets various contrast media products in India, such as Contrapaque (Iohexol), Lek Pamidol (Iopamidol), Trazograf (Diatrazoic acid), Trazogastro - Oral contrast (Diatrazoic acid), Magnilek Injection (Gadopentatic acid) and Cardiolek Injection (Iodixanol). The Company's brands for the Indian pharmaceutical market include Metrogyl (Metronidazole), Nicardia (Nifedipine), Rantac (Ranitidine), Dicloran (Diclofenac Sodium), OF (Ofloxacin), Cilacar (Cilnidipine) and Zecuf herbal. It manufactures generic products for the regulated markets and branded formulations for the emerging markets. It manufactures various APIs, such as Cilnidipine, Diclofenac Acid and Gadopentatic acid.